ABT-418 is a drug developed by Abbott which acts as an agonist at neural nicotinic acetylcholine receptors. It binds with high affinity to the α4β2 α2β2 and α7 subtypes but not to the α3β4 subtype. It has nootropic neuroprotective and anxiolytic effects and has been researched for treatment of both Alzheimer’s disease and more recently ADHD.
This page contains content from the copyrighted Wikipedia article "ABT-418"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
